skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Crenolanib (Code C64639)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Crenolanib

Definition: An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.

Label: Crenolanib

NCI Thesaurus Code: C64639 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831982  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-
PDGFR Inhibitor CP-868596

External Source Codes: 
CAS Registry Number 670220-88-9 (see NLM ChemIDplus info)
UMLS CUI C1831982

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C26H29N5O2
code C64639
Contributing_Source FDA
Legacy_Concept_Name CP-868_596
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom